PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 19, 2026Pharmaceutics2 citationsOpen Access

Quality by Design-Based Scale-Up and Industrial Development of Turmeric Extract-Loaded Nanostructured Lipid Carriers

View Full Paper
WJWipanan JandangPSPhennapha SaokhamCPChidchanok Prathumwon

Key Points

  • This research aims to develop a scalable manufacturing framework for curcuminoids-loaded nanostructured lipid carriers (NLCs) using Quality by Design principles.
  • Implemented a risk-based, knowledge-driven single-factor screening approach.
  • Defined critical quality attributes including particle size and zeta potential.
  • Optimized a two-step homogenization process using high-shear and high-pressure homogenization.
  • Utilized multivariate data analysis techniques such as principal component analysis and hierarchical cluster analysis.
  • Achieved successful scale-up of NLCs from 100 g to 5000 g capacity.
  • Generated nanosized particles within 100–500 nm with high encapsulation efficiency.
  • Demonstrated improved uniformity and physical stability using combined HSH and HPH methods.

Abstract

Background/Objectives: A robust and scalable manufacturing framework for lipid-based nanocarriers remains a critical challenge, particularly for labile phytochemicals such as curcuminoids in turmeric. This study presents an integrated Quality by Design (QbD)-driven and Outcome-Based Design (ObD) strategy to establish a scalable, resource-efficient manufacturing process for curcuminoids-loaded nanostructured lipid carriers (NLCs). Methods: To overcome the limitations of conventional multivariate design of experiments (DOE), which require extensive experimental runs, a risk-based, knowledge-driven single-factor screening approach was employed. Guided by risk assessment tools, including Ishikawa diagrams and failure mode considerations, 12 representative processing conditions were selected to define the design space. Critical quality attributes (CQAs), namely, particle size, polydispersity index (PDI), and zeta potential, were predefined to establish a robust control strategy. A two-step homogenization process—high-shear homogenization (HSH) for pre-emulsification followed by high-pressure homogenization (HPH) for nanoscale refinement—was systematically optimized. Results: Multivariate data analysis using principal component analysis (PCA) and hierarchical cluster analysis (HCA) identified key critical process parameters (CPPs), particularly HSH speed, processing time, and HPH cycles, as dominant factors influencing nanoparticle characteristics. The optimized 1-h process enabled successful scale-up of NLCs from 100 g to 5000 g, demonstrating the capability to generate nanosized particles within 100–500 nm. The combined HSH–HPH approach produced smaller, more uniform nanoparticles with high encapsulation efficiency and physical stability, outperforming HSH alone. Conclusions: Overall, this study establishes a practical and industrially viable framework that integrates QbD principles with data-driven optimization tools, for enabling reliable translation from laboratories to semi-industrial production.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Jandang et al. (2026) studied this question.

synapsesocial.com/papers/69e473de010ef96374d8f97ehttps://doi.org/10.3390/pharmaceutics18040492
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Natural Stabilizers and Nanostructured Lipid Carrier Entrapment for Photosensitive Compounds, Curcumin and Capsaicin2024 · 19 citations
  2. 2Effect of high shear homogenization on rheology, microstructure and fractal dimension of acid-induced SPI gels2013 · 86 citations
  3. 3A multivariate formulation and process development platform for direct compression2022 · 29 citations
  4. 4Nanostructured lipid carriers (NLC) in cosmetic dermal products☆2007 · 696 citations
  5. 5Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities2018 · 653 citations